UBR7 antibody
Principal name
UBR7 antibody
Alternative names for UBR7 antibody
C14orf130, N-recognin-7, Putative E3 ubiquitin-protein ligase UBR7
Ncbi ID
9606, NP_786924, AAH15046, NM_175748, NP_786924.2, NM_025666, NM_018108, NM_001100417
Available reactivities
Available hosts
Available applications
ELISA (detection) (E(detection)), Western blot / Immunoblot (WB), Paraffin Sections (P)
Background of UBR7 antibody
- Kit Component:
- - KN215315G1, C14orf130 gRNA vector 1 in pCas-Guide vector
- KN215315G2, C14orf130 gRNA vector 2 in pCas-Guide vector
- KN215315D, donor vector containing left and right homologous arms and Luciferase-Puro functional cassette
- GE100003, scramble sequence in pCas-Guide vector - CRISPR Manual:
- CRISPR/CAS9 Genome Editing Manual
General readings
Isogai,T. Unpublished (2002)
Western Blot analysis of UBR7 expression in transfected 293T cell line (H00055148-T01) by UBR7 MaxPab polyclonal antibody.Lane 1: C14orf130 transfected lysate(30.14 KDa).Lane 2: Non-transfected lysate.
UBR7 MaxPab polyclonal antibody. Western Blot analysis of UBR7 expression in NIH/3T3.
C14orf130 MaxPab polyclonal antibody. Western Blot analysis of C14orf130 expression in Jurkat.
UBR7 MaxPab polyclonal antibody. Western Blot analysis of UBR7 expression in Raw 264.7.
UBR7 MaxPab polyclonal antibody. Western Blot analysis of UBR7 expression in PC-12.
Human kidney; C14orf130 antibody - middle region (ARP43242_T100) in Human kidney cells using Immunohistochemistry
Human Jurkat; WB Suggested Anti-C14orf130 Antibody Titration: 2.5ug/ml. Positive Control: Jurkat cell lysate. UBR7 is supported by BioGPS gene expression data to be expressed in Jurkat.; C14orf130 antibody - middle region (ARP43242_T100) in Human Jurkat cells using Western Blot
Human kidney; C14orf130 antibody - C-terminal region (ARP43243_T100) in Human kidney cells using Immunohistochemistry
Human Jurkat; WB Suggested Anti-C14orf130 Antibody Titration: 1.25ug/ml. Positive Control: Jurkat cell lysate. UBR7 is supported by BioGPS gene expression data to be expressed in Jurkat.; C14orf130 antibody - C-terminal region (ARP43243_T100) in Human Jurkat cells using Western Blot
Transfected 293T; WB Suggested Anti-C14orf130 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:62500. Positive Control: Transfected 293T; C14orf130 antibody - N-terminal region (ARP43461_P050) in Transfected 293T cells using Western Blot
WB Suggested Anti-C14orf130 Antibody Titration: 2.5 ug/ml; Positive Control: Jurkat cell lysateUBR7 is supported by BioGPS gene expression data to be expressed in Jurkat
Human kidney
WB Suggested Anti-C14orf130 Antibody Titration: 1.25 ug/ml; Positive Control: Jurkat cell lysateUBR7 is supported by BioGPS gene expression data to be expressed in Jurkat
Human kidney
Host: Rabbit; Target Name: Ubr7; Sample Tissue: Rat Liver lysates; Antibody Dilution: 1.0ug/ml
WB Suggested Anti-C14orf130 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1: 62500; Positive Control: Transfected 293T
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP318298 | UBR7 (transcript variant 2) |
||||
| Recombinant protein of human ubiquitin protein ligase E3 component n-recognin 7 (putative) (UBR7), transcript variant 2 | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€748.00
|
|
| OriGene Technologies, Inc. | |||||
Lysates
| Catalog No. | ||
|---|---|---|
| LY403580 | UBR7 overexpression lysate |
|
 |
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. |
Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR206771L2V | Lenti ORF particles, Ubr7 (GFP-tagged) - Mouse ubiquitin protein ligase E3 component n-recognin 7 (putative) (Ubr7), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€930.00
|
|
| OriGene Technologies, Inc. | ||
| MR206771L1V | Lenti ORF particles, Ubr7 (Myc-DDK-tagged) - Mouse ubiquitin protein ligase E3 component n-recognin 7 (putative) (Ubr7), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€830.00
|
|
| OriGene Technologies, Inc. | ||
